

Tumor Necrosis Factor Inhibitors Market & Clinical Pipeline Outlook 2022

<https://marketpublishers.com/r/T8ACBD30B72EN.html>

Date: November 2016

Pages: 600

Price: US\$ 2,400.00 (Single User License)

ID: T8ACBD30B72EN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

“Tumor Necrosis Factor Inhibitors Market & Clinical Pipeline Outlook 2022” report by Kuick Research analyzes ongoing clinical and non-clinical trends in the global Tumor Necrosis Factor Inhibitors market. The anti TNF drugs are among the top 10 global block buster drugs and have dominated the global pharmaceutical market landscape for many years. The anti TNF Drugs (Humira, Remicade & Enbrel) for Rheumatic Disease have combined sales of more than US\$ 30 Billion in 2015. The multiple approaches used in development of Anti-TNF drugs along with the function of Tumor Necrosis Factor in Immune Mediated Inflammatory Diseases, Neurodegenerative Disorders and development of Cancer are explained in the report. Currently there are 151 Tumor Necrosis Factor Inhibitors in clinical pipeline and 25 Tumor Necrosis Factor Inhibitors are commercially available in the market.

Tumor Necrosis Factor consists of a pleiotropic cytokine, regulating various cellular and biological events such as immune and inflammatory responses, cell differentiation and proliferation, apoptosis and energy metabolism. The cellular source of TNF depends on the nature of the stimulus. Tumor necrosis factor is produced primarily by the cells of hematopoietic origin, including myeloid lineage such as monocyte and macrophages.

Over the past decade the pharmaceutical agents directed against TNF- α , infliximab, adalimumab and Etanercept, have been widely and successfully employed for the management of rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriasis, psoriatic arthritis, juvenile idiopathic arthritis and inflammatory bowel disease, and however two novel anti-TNF- α agents such as golimumab and certolimumab pegol, recently entered the market for the treatment of RA, AS, Crohn's disease and psoriasis.

The encouragement of the research by the positive results obtained from the use of TNF- α antagonists in terms of efficacy and safety and due to the increasingly collecting the evidence regarding the implication of TNF- α in the pathogenesis of numerous disorders and the anti-TNF- α agents have been considered for the management of diseases other than the ones they were initially approved for.

Anti-tumor necrosis factor (TNF) therapy is a valid, effective and increasingly used option in inflammatory bowel disease management. However, the further knowledge and therapeutic indications regarding the drugs are still growing. Anti-TNF therapy may be essential to achieve the recently projected end points and the prevention of bowel damage and prevention of patient's disability.

Anti-TNF drugs are also recommended to be more operative in early disease, particularly in early Crohn's disease. Moreover, its efficiency for prevention of postoperative recurrence in Crohn's disease is still debated. Costs and adverse effects, the significance of drug monitoring and the possibility of anti-TNF therapy withdrawal in selected patients are still debated issues. The reviews are expected to describe and discuss the most relevant data about the progress with anti-TNF therapy for the organization of inflammatory bowel disease.

“Tumor Necrosis Factor Inhibitors Market & Clinical Pipeline Outlook 2022” Report Highlight:

Overview of Tumor Necrosis Factor Inhibitors

Approaches Used in Development of Anti-TNF

TNF Inhibitors Market Overview

Tumor Necrosis Factor as an Anti-Cancer Agent

Global Tumor Necrosis Factor Inhibitors Pipeline by Company, Indication & Phase

Global Tumor Necrosis Factor Inhibitors Pipeline: 151

Marketed Tumor Necrosis Factor Inhibitors: 25

Contents

1. INTRODUCTION TO TUMOR NECROSIS FACTOR (TNF)

- 1.1 Basic Structure of the Tumor Necrosis Factor (TNF) Molecule
- 1.2 Significance of Tumor Necrosis Factor for the Biosynthesis Regulation
 - 1.2.1 Regulation of TNF Biosynthesis at the Transcriptional Level
 - 1.2.2 Regulation the TNF at the Receptor Level
- 1.3 Tumor Necrosis Factor Receptors

2. TUMOR NECROSIS FACTOR RECEPTOR SIGNALING PATHWAY

- 2.1 Tumor Necrosis Factor Receptor1 (TNFR1) Signaling
- 2.2 Tumor Necrosis Factor Receptor 2 (TNFR 2) Signaling

3. OVERVIEW OF TUMOR NECROSIS FACTOR INHIBITORS

- 3.1 Mechanism of Action of Tumor Necrosis Factor Inhibitors
- 3.2 Mechanism of Action of Remicade in the Inflammatory Diseases
- 3.3 Mechanism of Action of the Etanercept
- 3.4 Mechanism of Action of Humira

4. APPROACHES USED IN DEVELOPMENT OF ANTI-TNF

- 4.1 Monoclonal Antibody Approach
- 4.2 Recombinant DNA Technology Approach

5. FUNCTION OF TNF IN IMMUNE MEDIATED INFLAMMATORY DISEASES

- 5.1 Rheumatoid Arthritis
- 5.2 Crohn's Disease
- 5.3 Psoriasis & Psoriatic Arthritis

6. INVOLVEMENT OF TNF & ITS RECEPTOR IN NEURODEGENERATIVE DISORDERS

- 6.1 Alzheimer's Diseases
- 6.2 Parkinson's Diseases
- 6.3 Ischemic Stroke

6.4 Multiple Sclerosis

7. ROLE OF THE TUMOR NECROSIS FACTOR IN THE DEVELOPMENT OF THE CANCER

7.1 Introduction

7.2 Tumor Necrosis Factor as Carcinogen

7.3 Tumor Necrosis Factor as an Anti-Cancer Agent

8. TNF INHIBITORS MARKET OVERVIEW

8.1 Market of Anti-TNF Blockbuster Drugs

8.1.1 Market of Humira

8.1.2 Market of Enbrel

8.1.3 Market of Remicade

8.2 Global Tumor Necrosis Factor Inhibitors Pipeline Overview

9. GLOBAL TNF INHIBITORS MARKET DYNAMICS

9.1 Accelerative Parameters to the TNF Inhibitor Market

9.2 Challenges to the TNF Inhibitor Market

10. FUTURE IMPLICATIONS OF TNF INHIBITOR MARKET

11. GLOBAL TUMOR NECROSIS FACTOR INHIBITORS PIPELINE BY COMPANY, INDICATION & PHASE

11.1 Unknown

11.2 Research

11.3 Preclinical

11.4 Clinical

11.5 Phase-I

11.6 Phase-I/II

11.7 Phase-II

11.8 Phase-II/III

11.9 Phase-III

11.10 Preregistration

11.11 Registered

12. MARKETED TUMOR NECROSIS FACTOR INHIBITORS CLINICAL INSIGHT

- 12.1 Lumbricus Rubellus Extract (Disolf)
- 12.2 Certolizumab Pegol (Cimzia, Simziya)
- 12.3 Apremilast (Otezla)
- 12.4 Lenalidomide (Ladevina, Revlimid)
- 12.5 Adalimumab (Humira, Raheara)
- 12.6 Etanercept (Enbrel)
- 12.7 Infliximab Biosimilar (Inflectra, Remsima)
- 12.8 Adalimumab Biosimilar
- 12.9 Pomalidomide (Imnovid, Pomalyst)
- 12.10 Belimumab (Benlysta)
- 12.11 Etanercept Biosimilar (Infiniteam)
- 12.12 Golimumab (Simponi)
- 12.13 Infliximab Biosimilar (Infimab)
- 12.14 Infliximab (Remicade)
- 12.15 Etanercept Biosimilar (Intacept)
- 12.16 Iguratimod (Careram, Kolbet)
- 12.17 Thalidomide (Thaled, Thalidomide Celgene, Thalomid)
- 12.18 Infliximab Biosimilar
- 12.19 Adalimumab Biosimilar (Exemptia)
- 12.20 Etanercept Biosimilar (Iran)
- 12.21 Etanercept Biosimilar (Etacept, Etanar, Yisaipu)
- 12.22 Iguratimod
- 12.23 Anti-Tumour Necrosis Factor-Alpha Antibody Oral
- 12.24 Pentoxifylline (Claudicat, Dospan Pento, Elorgan, Pentoxifilina, Trental)
- 12.25 Sho-seiryu-to

13. TNF INHIBITORS SUSPENDED IN CLINICAL PIPELINE

- 13.1 No Development Reported
- 13.2 Discontinued
- 13.3 Suspended

14. COMPETITIVE LANDSCAPE

- 14.1 AbbVie
- 14.2 Ablynx
- 14.3 Apogenix

- 14.4 AryoGen Biopharma
- 14.5 Bionovis
- 14.6 CASI Pharmaceuticals
- 14.7 Celltrion
- 14.8 Celgene Corporation
- 14.9 Delenex Therapeutics
- 14.10 Dexa Medica
- 14.11 EPIRUS Biopharmaceuticals
- 14.12 Janssen Biotech
- 14.13 GlaxoSmithKline
- 14.14 HanAll Biopharma
- 14.15 Intas Pharmaceuticals
- 14.16 LEO Pharma
- 14.17 LG Life Sciences
- 14.18 MedImmune
- 14.19 Momenta Pharmaceuticals
- 14.20 Novartis
- 14.21 PROBIOMED
- 14.22 Reliance Life Sciences
- 14.23 Sandoz
- 14.24 Samsung Bioepis
- 14.25 Sanofi-Aventis
- 14.26 Shanghai CP Guojian Pharmaceutical
- 14.27 Shanghai Pharmaceuticals
- 14.28 Simcere Pharmaceutical
- 14.29 Toyama Chemical
- 14.30 Tsumura
- 14.31 UCB
- 14.32 Zydus Cadila

List Of Figures

LIST OF FIGURES

- Figure 1-1: Structure of the Tumor Necrosis Factor Molecule
- Figure 1-2: Regulation of the Tumor Necrosis Factor Biosynthesis & Bioavailability
- Figure 1-3: Structure of Tumor Necrosis Factor Receptor
- Figure 1-4: Structure of Tumor Necrosis Factor Receptor
- Figure 2-1: Signaling Pathway of Tumor Necrosis Factor Receptor1 (TNFR1)
- Figure 2-2: Tumor Necrosis Factor Receptor 2 Signaling Pathway (TNFR 2)
- Figure 3-1: Remicade Mechanism of Action
- Figure 3-2: Etanercept Mode of Action
- Figure 3-3: Humira Mechanism of Action
- Figure 4-1: Methods for the Anti-TNF Production
- Figure 5-1: Tumor Necrosis Factor in Rheumatoid Arthritis
- Figure 5-2: Global - Top Anti-Rheumatic Drug Sales (US\$ Million), 2015 & 2022
- Figure 5-3: Anti-TNF Therapy for the Treatment of Rheumatoid Arthritis
- Figure 5-4: Molecular Targets of TNF Antagonists in Crohn's Disease
- Figure 5-5: Tumor Necrosis Factor in Psoriatic Arthritis
- Figure 7-1: Tumor Necrosis Factor in the Cancer Initiation
- Figure 7-2: Role of Tumor Necrosis Factor as an Anti-Cancer Agent
- Figure 8-1: Blockbuster Anti-TNF Drugs (US\$ Billion), 2015
- Figure 8-2: Blockbuster TNF Inhibitors for Rheumatic Disease (US\$ Billion), 2015 & 2022
- Figure 8-3: Humira - Global Sales (US\$ Billion), 2011-2015 & 2022
- Figure 8-4: Enbrel - Global Sales (US\$ Billion), 2011-2015 & 2022
- Figure 8-5: Market Price of Enbrel & Etaccept (USD)
- Figure 8-6: Remicade - Global Sales (US\$ Billion), 2011-2015 & 2022
- Figure 8-7: Market Price of Remicade & Infimab (USD)
- Figure 8-8: Global - Tumor Necrosis Factor Inhibitors Pipeline by Phase (%), 2016 till 2022
- Figure 8-9: Global - Tumor Necrosis Factor Inhibitors Pipeline by Phase (Numbers), 2016 till 2022
- Figure 8-10: Global - Tumor Necrosis Factor Inhibitors Suspended & Discontinued in Pipeline by Phase (%), 2016
- Figure 8-11: Global - Tumor Necrosis Factor Inhibitors Suspended & Discontinued in Pipeline by Phase (Number), 2016
- Figure 9-1: Favorable Parameters of Anti-TNF Drugs
- Figure 9-2: Limitation Factors for the Anti-TNF Drug Market

- Figure 14-1: Ablynx - Clinical Pipeline
- Figure 14-2: Apogenix - Clinical Pipeline
- Figure 14-3: Casi Pharmaceutical - Clinical Pipeline
- Figure 14-4: Celgene - Clinical Pipeline
- Figure 14-5: EPIRUS Biopharmaceuticals - Clinical Pipeline
- Figure 14-6: HanAll Biopharma - Clinical Pipeline
- Figure 14-7: Novartis - Clinical Pipeline
- Figure 14-8: Sandoz - Clinical Pipeline
- Figure 14-9: Toyama Chemical - Clinical Pipeline
- Figure 14-10: Zydus Cadila - Clinical Pipeline

I would like to order

Product name: Tumor Necrosis Factor Inhibitors Market & Clinical Pipeline Outlook 2022

Product link: <https://marketpublishers.com/r/T8ACBD30B72EN.html>

Price: US\$ 2,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T8ACBD30B72EN.html>